Cancer is much easier to prevent than treat.

In the United States, approximately 70% of all cancer patients have metastasized cancer when they are first diagnosed.  In other words, in the majority of people cancer has been slowly progressing for 2 to 15 years before a symptom developed or medical testing is done to make the diagnosis.

Since the treatment of advanced cancer is challenging, often with poor 5 year survival rates, it is important to detect the disease at its earliest stages when it is more likely to be reversed.

The “terrain” or “internal milieu” of the body (and mind) deteriorates gradually over several years thereby allowing a renegade cancer cell to become a tumor which can be diagnosed by medical tests. We can measure some of these changes, such as C-reactive protein and fibrinogen which signal chronic inflammation.

Chronic insulin resistance is another contributor to weakened body resistance, as is high cholesterol and weak immune function.  The gradual build-up of chemical toxins and heavy metals may contribute to the mutational changes seen in aberrant cancer cell growth.  And finally, chronic stress which does not seem resolvable may be the final and crucial burden to the body’s extensive protective systems.

Dr. Emil Shandl has worked for years in the early detection of cancer and has developed the CA Profile, which isa lab test that is also based on the premise that detectable biochemical changes occur in the human body during its transformation into a cancerous state.

The CA Profile is composed of 8 tests:

  • HCG  is human chorionic gonadotropin, which is tested under 3 different methodologists, serum chemiluminescence assay and immunoradiometric assay, and urine quantitative chemiluminescence assay,
  •  PHI  is phosphohexose isomerase enzyme,
  • CEA  is carcinoembryonic antigen,
  • GGTP is  gamma-glutamyltranspeptidase,
  • TSH  is thyroid-stimulating hormone),
  •  DHEA-S is dehydroepiandrosterone sulfate)

Dr. Schandl developed his battery of tests after a great deal of reading, testing and experimentation at the Howard Hughes Research Institute in Miami, and at local hospitals in South Florida. He has observed marker elevations in patients as many as 10 to 12 years prior to diagnosis.

Knowing that the developmental process of cancer takes 10 to12 years, one may be able to detect the very beginning of cancer, allowing plenty of time to make lifestyle adjustment corrections in order to avoid possibly catastrophic consequences. It should be noted that the CA Pofile is excellent not only for early detection, but also clinical laboratory follow-up and monitoring disease reduction or progression.

shutterstock_263085572While numerous studies have confirmed that HCG levels are elevated in the presence of cancer cells in the body, a caveat in using HCG alone as a tumor marker is that it may be present in super-low quantities that cannot be detected, even by existing technology. Therefore, the CA Profile includes other tumor markers as well.  In other words, what one test may miss, the other(s) will usually detect.

Consider the fact, testing for HCG alone can result in approximately 30% false negative results. The entire CA Profile may miss only 10-15% cancer positive patients.

In a study reported in 1987, the tumor marker CEA proved to be sensitive in cases of metastasized bone cancer, while PHI was elevated in cancers of other organs. However, when CEA and PHI were combined, overall sensitivity was increased considerably [Paulick, R., et al., Cancer Detect Prev, 1987, 10 (3-4): 197-203].

The Cancer Profile combines a number of tests which, by themselves, might not be indicative enough, but together they provide an impressive level of accuracy and precision.

Studies have shown that, when testing patients who were known to have cancer, 68 percent showed elevated HCG levels.  When the measurement was for the enzyme PHI, levels were elevated in 36 percent of the patients; GGTP levels were high in 39 percent of patients; and a test forCEA showed elevated levels in 51 percent of patients.

When combining specific tests and using more refined technology, Dr. Schandl’s CA Profile produced more persuasive results:
The CA Profile panel has an impressive accuracy of 87-97%.

Looking at three cancer markers together (HCG, PHI, CEA), 221 positives in 240 breast cancer patients (92 percent) were detected. Of lung-cancer patients, 127 of 129 (97 percent) were correctly diagnosed. And with colon-cancer patients, 55 positives out of 59 patients (93 percent) were correctly identified.

Also included in the profile are the DHEA-S, TSH, and GGTP tests. These are peripherally related to cancer. The rationale is that people with either low thyroid activity or low adrenal activity, or abnormal GGTP results seem to be predisposed to cancer.

When the CA Profile indicates a probability for the development of cancer, then you can make the necessary changes to improve the terrain of the body and mind.  These changes include a high fiber, whole food diet with reduced or eliminated animal products, as well as nutrient supplementation of various kinds, including immune stimulation.

You can also determine the body burden for heavy metals and chemicals such as phthalates and benzene, which are found in everyone on the planet at this time. And, the stress issues can be re-evaluated and changed when a person is given a new perspective and appropriate tools to transform the challenges in life into growth and health.

The CA Profile is available at MindBody Medicine Center and the cost is $300.